A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia

Blood

Volumn 100, Issue 9, 2002, Pages 3423-3425

  Spiekermann, Karsten ^a   Bagrintseva, Ksenia ^a   Schoch, Claudia ^a   Haferlach, Torsten ^a   Hiddemann, Wolfgang ^a   Schnittger, Susanne ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DNA; FLT3 LIGAND; IDARUBICIN; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; AGED; ARTICLE; CASE REPORT; CELL GROWTH; CYTOGENETICS; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036839326     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0953     Document Type: Article

References (24)

1. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14:796-804.
2. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication the fit3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918.
3. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
4. Whitman SP, Archer KJ, Feng L, et al. Absence of the w'd-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B Study. Cancer Res. 2001;61:7233-7239.
5. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia (AML): correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study, and usefulness as a marker for detection of minimal residual disease. Blood. 2002;100:59-66.
6. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
7. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Fit3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94.
8. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
9. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113:983-988.
10. Lyman SD, Jacobsen SE. c-kit ligand and Fit3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood. 1998;91:1101-1134.
11. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit, Proc Natl Acad Sci U S A. 1991;88:9026-9030.
12. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Fit3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene. 1991;6:1641-1650.
13. Mizuki M, Fenski R, Halfter H, et al. Fit3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907-3914.
14. Hayakawa F, Towalari M, Kiyoi H, et al. Tandemduplicated Fit3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
15. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12:1333-1337.
16. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99:310-318.
17. Baldwin BR, Tse KF, Small D. Transgenic mice expressing a constitutively activated FLT3 receptor display a myeloproliferative disease phenotype, Blood. 2001;98:801a.
18. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. Leukemia. 2002;16:53-59.
19. ISCN Guidelines for cancer cytogenetics, supplement to an International System for Human Cytogenetic Nomenclature. In: F Mitelman, ed. Basel, Switzerland: S. Karger; 1995.
20. Nakao M, Janssen JW, Seriu T, Bartram CR. Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using Light Cycler technology. Leukemia. 2000;14:312-315.
21. Spiekermann K, Schwab R, Pau M, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activalion of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol. 2002;30:262-271.
22. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000;14:1766-1776.
23. Tse KF, Novelli E, Civin Cl, Bohmer FD, Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. 2001;15:1001-1010.
24. Levis M, Tse KF, Smith BD, Garrett E, Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001;98:885-887.